新加坡在特朗普推迟对品牌药品征收100%的税后, 寻求有利的美国药品关税。 Singapore seeks favorable U.S. drug tariffs after Trump delays 100% tax on branded pharmaceuticals.

自2025年10月1日起,特朗普政府推迟对进口品牌药品实行100%的关税,此后,新加坡正在与美国谈判,争取为其药品出口达成优惠关税交易。 Singapore is negotiating with the U.S. to secure a preferential tariff deal for its pharmaceutical exports after the Trump administration delayed implementing a 100% tariff on imported branded drugs, effective October 1, 2025. 拖延为讨论留出了时间,因为新加坡寻求与日本和韩国相似的条件。 The delay allows time for discussions, as Singapore seeks terms similar to those with Japan and South Korea. 该国主要向美国出口活性药物原料,从2022年到2024年,平均每年出口28-37亿美元。 The country exports primarily active pharmaceutical ingredients to the U.S., averaging $2.8–3.7 billion annually from 2022 to 2024. 主要的全球毒品制造者,如辉瑞、默克和诺华在新加坡有业务。 Major global drugmakers like Pfizer, Merck, and Novartis have operations in Singapore. 一些公司正在扩大或建设美国设施,以获得关税豁免的资格,而政府则努力保护其关键产业,并在全球贸易不确定的情况下吸引投资。 Some firms are expanding or building U.S. facilities to qualify for tariff exemptions, while the government works to protect its key industry and attract investment amid global trade uncertainty.